Nuvation Bio Inc. NUVB
4.29 USD +0.09 (+2.14%)
At closeNov 11, 2026, 7:49 PM EST
4.26 -0.03 -0.70%
After hours · Nov 11, 7:49 PM ET
4.22 Day range 4.38
3.98 52-week range 9.75
- YTD
- -52.12%
- 1 year
- -13.86%
News
prnewswire.com Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David…
seekingalpha.com Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks Patients Nuvation Bio's Ibtrozi's roughly 50-month first-line durability means revenue depends on patients staying on therapy, not just new starts. Q3 Ibtrozi revenue rose 18% sequentially to $27.5 million,…
marketbeat.com What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call Nuvation Bio NYSE: NUVB reported $45 million in third-quarter 2026 revenue as U.S. sales of lung cancer treatment IBTROZI rose 18% from the previous quarter, even as the company said new patient…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
benzinga.com RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17 RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $17.
seekingalpha.com Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript
zacks.com Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.16 per share a year ago.
benzinga.com Nuvation Bio Q3 2026 Earnings Call Transcript Nuvation Bio (NYSE:NUVB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
benzinga.com Nuvation Bio Q3 EPS $(0.12), Inline, Sales $44.951M Beat $34.224M Estimate Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(0.16) per share from the same period…
prnewswire.com Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and…
benzinga.com Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual Meeting Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional updated results from the Phase 2…
prnewswire.com Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting Nuvation Bio will present four posters: one will showcase updated long-term Phase 2 results; three posters highlight trial in progress overviews for ongoing safusidenib studies Poster featuring Phase…
benzinga.com Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the pivotal Phase 3 SIGMA (G203; NCT05303519)…
prnewswire.com Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries New sites in the UK, France, Sweden, Germany, Italy and Spain will add to the global footprint of the pivotal SIGMA study NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a…
prnewswire.com Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026 NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today…
benzinga.com This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage: Buy on FORM ($200), NUVB ($12); Outperform on CIEN ($440); Neutral on EXPD ($180); Equal-Weight on SFD ($22).
defenseworld.net Nuvation Bio Inc. (NYSE:NUVB) Stock Rated “Moderate Buy” by Wall Street Analysts Shares of Nuvation Bio Inc. (NYSE: NUVB - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve analysts that are currently covering the company, Marketbeat.com reports.…
benzinga.com Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12 Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.
benzinga.com Why Is Nuvation Bio Stock Gaining Thursday? Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 years of clinical benefit in ROS1+ NSCLC.
benzinga.com Nuvation Bio Says FDA Approves sNDA For IBTROZI, ROS1 Inhibitor For Treatment Of Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 monthsNo changes to the safety sections of labeling with longer follow-up and no new safety signals…
prnewswire.com Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes to the safety sections of labeling with longer follow-up and no new safety signals identified…- benzinga.com Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target Citizens analyst Silvan Turkcan reiterates Nuvation Bio (NYSE:NUVB) with a Market Outperform and maintains $10 price target.
- benzinga.com Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
seekingalpha.com Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript- benzinga.com Nuvation Bio Announces New Subgroup Analyses From Pivotal TRUST-I And TRUST-II Studies Evaluating IBTROZI In Both TKI- Naïve And TKI-Pretreated Patients With Advanced ROS1+ NSCLC Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1…
prnewswire.com Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1…
seekingalpha.com Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
benzinga.com Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is On CNBC's “Mad Money Lightning Round,” Jim Cramer said Nuvation Bio Inc. (NYSE:NUVB) is a “pure spec.”
benzinga.com Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is... Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.
zacks.com Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the…
prnewswire.com Nuvation Bio to Participate in Upcoming Investor Conferences NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David…
zacks.com Nuvation Bio (NUVB) Upgraded to Buy: Here's Why Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
benzinga.com This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.
benzinga.com This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Wall Street analysts upgraded Parsons Corp, InnovAge Holding Corp, Equifax Inc, and initiated coverage on Builders FirstSource, Inc and Nuvation Bio Inc.
benzinga.com This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.- benzinga.com Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1 Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant…
prnewswire.com Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma…
zacks.com Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…- benzinga.com JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13 JP Morgan analyst Priyanka Grover initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweight rating and announces Price Target of $13.
benzinga.com RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $20 RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $19 to $20.
benzinga.com Nuvation Bio Q2 EPS $(0.18) Beats $(0.19) Estimate, Sales $31.687M Beat $27.505M Estimate Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 5.88 percent decrease over losses of $(0.17)…- benzinga.com Nuvation Bio Announces New Subgroup Analyses Of Phase 2 TRUST-I And TRUST-II Data For IBTROZI In ROS1+ NSCLC Will Be Presented At WCLC And ESMO Presentations Overview:WCLCTitle: Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-IIPresenter: Hidetoshi Hayashi, Kindai…
benzinga.com HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $21 HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from $17 to $21.- benzinga.com Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
benzinga.com Why Is Nuvation Bio Stock Gaining Monday? Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its clinical trial pipeline.
benzinga.com AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings expectations. Other big gainers include NUAI, IREN, XNCR, HUT, CIFR, CLSK, NUVB, AXTI, ATEX, APLD, and…- benzinga.com Nuvation Bio Announces Positive Updated Phase 2 Data And Expansion From Safusidenib Clinical Trial In Newly-Diagnosed Grade 2 Glioma Patients Outside The U.S. Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-upNew Phase 3 study to evaluate…
- benzinga.com RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $19 RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $19.
- benzinga.com Truist Securities Maintains Buy on Nuvation Bio, Raises Price Target to $13 Truist Securities analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from $12 to $13.
benzinga.com H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release and offer to acquire Advanced Medical Solutions.